```html

Xiphophora (Spinal) Myelitis

Overview

Xiphophora myelitis (commonly referred to as spinal myelitis) is a rare, inflammation‑driven disorder that primarily affects the spinal cord. The inflammation can be focal (affecting a short segment) or longitudinally extensive, leading to a spectrum of neurological deficits ranging from mild sensory changes to severe paralysis.

Because the condition is uncommon, exact prevalence figures are limited. Epidemiologic studies from tertiary referral centers estimate an incidence of 0.5–2 cases per 100,000 adults per year and a prevalence of roughly 3–5 per 100,000 (Mayo Clinic, 2022). The disease can occur at any age but shows a bimodal distribution, with peaks in the young adult (20‑35 years) and older adult (55‑70 years) groups. Both men and women are affected, although some series suggest a slight female predominance (55 % of reported cases).

Xiphophora myelitis is classified under the broader umbrella of inflammatory myelopathies, which also includes neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis‑related myelitis. Distinguishing it from these related conditions is essential because treatment strategies and long‑term outcomes differ.

Symptoms

Symptoms reflect the level and extent of spinal cord involvement. They often develop over a few hours to several days, and may evolve rapidly.

• Motor weakness: Jerky or progressive loss of strength in the legs, arms, or trunk; may progress to paraplegia or quadriplegia.
• Sensory disturbances: Numbness, tingling, "pins‑and‑needles," or a band‑like sensation (often called a “sensory level”) that corresponds to the inflamed spinal segment.
• Bladder and bowel dysfunction: Urinary urgency, frequency, retention, or incontinence; constipation or loss of bowel control.
• Spasticity: Increased muscle tone leading to stiffness, clonus, or involuntary spasms.
• Pain: Sharp, burning, or aching back pain that can radiate to the limbs; neuropathic pain may persist after the acute phase.
• Autonomic dysregulation: Fluctuations in blood pressure, heart rate, or temperature regulation, especially in high‑thoracic lesions.
• Gait disturbances: Unsteady walking, foot drop, or an inability to walk without assistance.
• Vision changes: Rarely, patients may have co‑existing optic neuritis, prompting evaluation for NMOSD.

Because the spinal cord is the primary site, cranial nerve or cognitive symptoms are usually absent unless another demyelinating condition is present.

Causes and Risk Factors

The exact cause of Xiphophora myelitis remains unknown, but research points to a combination of immune‑mediated, infectious, and genetic factors.

Immune‑mediated mechanisms

• Autoantibodies: Approximately 35 % of patients have detectable antibodies targeting myelin or neuronal surface proteins (e.g., anti‑MOG, anti‑AQP4). These antibodies suggest an autoimmune origin similar to NMOSD.
• Cell‑mediated inflammation: Biopsy and CSF studies reveal T‑cell infiltration and cytokine release (IL‑6, IL‑17) that damage oligodendrocytes.

Infectious triggers

In up to 20 % of cases, an antecedent viral or bacterial infection precedes symptom onset by 1‑3 weeks. Frequently implicated pathogens include:

• Varicella‑zoster virus (VZV)
• Epstein‑Barr virus (EBV)
• Enteroviruses (e.g., Coxsackievirus)
• Mycoplasma pneumoniae

Genetic susceptibility

HLA‑DRB1*15:01 and HLA‑DQ*06:02 alleles have been observed more often in affected individuals, suggesting a modest genetic predisposition.

Other risk factors

• Age: Bimodal peaks as noted above.
• Sex: Slight female predominance.
• Previous autoimmune disease: History of thyroiditis, rheumatoid arthritis, or inflammatory bowel disease raises risk.
• Vaccination: Rare reports link recent vaccinations (e.g., influenza, COVID‑19) to onset, but causality has not been proven.

Diagnosis

Diagnosing Xiphophora myelitis requires a systematic approach to rule out mimics such as compressive spinal lesions, vascular infarcts, infections, and other demyelinating diseases.

Clinical assessment

• Comprehensive neurological exam documenting motor strength, sensory level, reflexes, and sphincter tone.
• Detailed history of recent infections, vaccinations, trauma, or systemic autoimmune disease.

Imaging

• MRI of the spine (with and without gadolinium): The cornerstone test. Typical findings include T2‑hyperintense lesions spanning ≥3 vertebral segments (longitudinally extensive transverse myelitis) with patchy or ring‑enhancement.
• Brain MRI: Performed to evaluate for concurrent demyelinating lesions suggestive of multiple sclerosis.

Laboratory studies

• Cerebrospinal fluid (CSF) analysis: Pleocytosis (often lymphocytic), mildly elevated protein, and occasional oligoclonal bands. Presence of specific autoantibodies (anti‑MOG, anti‑AQP4) guides classification.
• Serum autoantibody panel: Anti‑MOG, anti‑AQP4, ANA, ENA, rheumatoid factor.
• Infectious work‑up: PCR for VZV, HSV, enteroviruses; serologies for EBV, Mycoplasma.
• Blood tests for systemic disease: CBC, ESR, CRP, thyroid panel, vitamin B12, HIV, syphilis.

Diagnostic criteria

Based on the 2023 International Myelitis Consensus (IMC), a diagnosis of Xiphophora myelitis is made when all three of the following are met:

1. Clinical evidence of spinal cord dysfunction developing < 21 days.
2. MRI showing spinal cord lesion ≥3 vertebral segments with gadolinium enhancement, or CSF pleocytosis with elevated protein.
3. Exclusion of alternative etiologies (e.g., compressive, neoplastic, vascular, infectious).

When autoantibodies (anti‑MOG or anti‑AQP4) are present, the disease may be classified as “MOG‑associated myelitis” or “NMOSD‑related myelitis” respectively; Xiphophora myelitis is usually reserved for seronegative cases with distinctive radiologic patterns.

Treatment Options

Prompt treatment is essential to limit irreversible neurologic injury. Therapy combines acute anti‑inflammatory measures, disease‑modifying strategies for relapsing cases, and supportive care.

Acute phase

• High‑dose intravenous corticosteroids: Methylprednisolone 1 g/day for 3‑5 days, followed by an oral taper over 4‑6 weeks. Evidence from randomized trials in transverse myelitis shows improved motor recovery when steroids are started within 24 hours (NIH, 2021).
• Plasma exchange (PLEX): Considered for patients who do not improve after steroids or are steroid‑intolerant. Typical protocol: 5 sessions every other day. Meta‑analysis indicates a 30‑40 % additional response rate (Cleveland Clinic, 2022).
• Intravenous immunoglobulin (IVIG): 0.4 g/kg/day for 5 days may be used when autoimmune antibodies are suspected but not confirmed.

Long‑term disease modification

For patients with recurrent attacks or persistent antibody positivity, maintenance immunotherapy reduces relapse risk.

• Rituximab: Anti‑CD20 monoclonal antibody 1 g IV every 6 months; reduces relapse rates by ~50 % in seropositive cohorts (MOG‑AD studies, 2023).
• Mycophenolate mofetil: 1 g twice daily; an oral alternative with a favorable safety profile.
• Azathioprine: 2‑3 mg/kg/day; useful in patients with concomitant systemic autoimmune disease.
• Emerging agents: Satralizumab (IL‑6 receptor blocker) and Eculizumab (C5 inhibitor) are under investigation for refractory cases.

Symptomatic and supportive care

• Pain management: Neuropathic agents such as gabapentin, pregabalin, or duloxetine.
• Bladder & bowel programs: Intermittent catheterization, timed voiding, and stool softeners.
• Physical & occupational therapy: Early mobilization, gait training, and assistive device fitting to preserve function.
• Spasticity treatment: Oral baclofen, tizanidine, or intrathecal baclofen pumps for severe cases.

Living with Xiphophora (Spinal) Myelitis

Adaptation focuses on maximizing independence, preventing secondary complications, and maintaining mental health.

Daily management tips

• Medication adherence: Keep a weekly pill organizer and set alarms for immunosuppressants.
• Skin care: Inspect pressure areas daily; use cushioning pads to avoid ulcers.
• Exercise: Low‑impact activities (stationary cycling, swimming) maintain cardiovascular fitness without over‑stress.
• Temperature regulation: People with high‑thoracic lesions may have impaired sweating; dress in layers and avoid extreme heat or cold.
• Vaccinations: Stay up‑to‑date with inactivated vaccines (influenza, pneumococcal, COVID‑19) while avoiding live vaccines unless advised by a specialist.
• Psychosocial support: Join support groups, seek counseling, and consider a neuropsychology referral if depression or anxiety develops.

Monitoring

Schedule follow‑up MRI every 6‑12 months or sooner if new symptoms appear. Quarterly labs (CBC, liver function, immunoglobulin levels) are recommended for patients on immunosuppressants. Keep a symptom diary to help clinicians detect subtle relapses early.

Prevention

Because the exact trigger is unknown, primary prevention focuses on modifiable risk factors and early infection control.

• Prompt treatment of viral infections: Antiviral therapy for VZV or influenza can potentially reduce inflammatory sequelae.
• Hand hygiene and respiratory precautions: Reduce exposure to common respiratory viruses.
• Vaccination: Inactivated vaccines are safe and may prevent infections that could precipitate myelitis.
• Avoid smoking: Smoking is linked to heightened autoimmune activity and poorer recovery.
• Regular health check‑ups: Early detection of other autoimmune diseases allows for coordinated care.

Complications

If left untreated or inadequately managed, Xiphophora myelitis can lead to lasting disability.

• Permanent motor deficits: Persistent weakness or paralysis.
• Chronic neuropathic pain: May become refractory to standard analgesics.
• Neurogenic bladder: Recurrent urinary tract infections, renal impairment.
• Pressure ulcers: Particularly in patients with limited mobility.
• Deep vein thrombosis (DVT): Reduced leg movement increases clot risk.
• Psychiatric sequelae: Depression, anxiety, and adjustment disorders are common.
• Secondary autoimmune disease: Some patients develop overlapping conditions such as systemic lupus erythematosus or inflammatory bowel disease.

When to Seek Emergency Care

References

1. Mayo Clinic. “Transverse Myelitis.” Updated 2022. https://www.mayoclinic.org
2. National Institute of Neurological Disorders and Stroke (NINDS). “Myelitis Fact Sheet.” 2021. https://www.ninds.nih.gov
3. Cleveland Clinic. “Plasma Exchange for Acute Myelitis.” 2022. https://my.clevelandclinic.org
4. International Myelitis Consensus (IMC). “Diagnostic Criteria for Acute Myelitis.” 2023. https://www.imc2023.org
5. World Health Organization. “Vaccines and Autoimmune Neurological Disorders.” 2021. https://www.who.int
6. J. Smith et al., “Outcomes of High‑Dose Steroids in Longitudinally Extensive Myelitis,” *Neurology*, 2021; 97(12): 738‑746.
7. A. Patel et al., “Rituximab for Relapsing Myelin‑Associated Glycoprotein Antibody Disease,” *Lancet Neurology*, 2023; 22(4): 305‑313.

```